NSAIDs/Corticosteroids - Primum non nocere

Advances in Experimental Medicine and Biology

Volumn 455, Issue , 1999, Pages 319-325

  Dequeker, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CORTISONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SEX HORMONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE MASS; BONE MINERAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG INDUCED DISEASE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0033282385     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4857-7_48     Document Type: Conference Paper

References (36)

1. Selective COX-2 inhibition: Relevance in arthritis
2. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
3. Toward and epidemiology of gastropathy associated with non-steroidal anti-inflammatory drugs use
4. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died
5. Anti-inflammatory drugs and upper gastrointestinal perforation
6. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
7. Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly ?
8. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
9. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
10. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
11. Towards a better aspirin
12. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non ulcerogenic
13. Does it make a difference? Experience with COX-2 inhibition in 10,000 osteoarthritis patients
14. Low dose corticosteroids associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: Bones of contention
15. Steroid osteoporosis. A pragmatic approach is needed while prospective trials are awaited
16. Corticosteroid osteoporosis
17. Steroid osteoporosis
18. Is steroid-induced osteoporosis preventable?
19. Osteoporosis and arthritis
20. Osteoporosis and its treatment
21. Steroid induced osteoporosis: An opportunity for prevention ?
22. Osteoporosis in rheumatological practice: Questions to be answered
23. Locomotor side-effects of corticosteroids
24. Kortikoide, Knochenmasse und Frakturen bei rheumatischen Erkrankungen
25. Reduction of serum testosterone levels during chronic glucocorticoid therapy
26. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose long-term effects of prednisone versus deflazacort
27. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis
28. The effect of calcium supplementation on the circadian rhythm of bone resorption
29. Effect of one late evening dose of calcium on bone resorption in postmenopausal women
30. Calcium supplements in the prevention of steroid-induced osteoporosis
31. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia
32. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients
33. Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D
34. Calcitonin, Etidronate, and Calcidiol treatment in bone loss after cardiac transplantation
35. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial